Crossmark

Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia

Crossref DOI link: https://doi.org/10.1007/s10549-020-05730-2

Published Online: 2020-06-10

Published Print: 2020-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Jinfeng

Lin, Mingxi

Jin, Yizi

Gu, Linhan

Li, Ting

Yuan, Baoying

Wang, Biyun

Wang, Leiping

Zhang, Sheng

Cao, Jun

Tao, Zhonghua

Zhang, Jian https://orcid.org/0000-0003-3208-3106
Hu, Xichun
Funding

Funding for this research was provided by:

Science and Technology Commission of Shanghai Municipality (18411967800)

Shanghai Municipal Population and Family Planning Commission (201640069)

Natural Science Foundation of Shanghai (17ZR1405700)

Damon Runyon Cancer Research Foundation (Y-2019Roche-171)

Shanghai Hospital Development Center (SHDC12018X03)
License Information

Text and Data Mining valid from 2020-06-10

Version of Record valid from 2020-06-10
More Information

Article History

Received: 11 April 2020

Accepted: 5 June 2020

First Online: 10 June 2020

Compliance with ethical standards

:

: The authors declare that there are no conflicts of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the FUSCC Ethics Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below